Last reviewed · How we verify
Assessment of Seizure Prophylaxis Protocols Using Intravenous Levetiracetam in a Neuroscience Intensive Care Unit (Keppra)
To show that the use of intravenous levetiracetam(LEV;Keppra)for seizure prevention in patients in the Neuroscience Intensive Care Unit will result in fewer side effects compared to the current standard of care anticonvulsant and will be at least as effective as the current standard of care in preventing clinical and sub-clinical seizure activity.
Details
| Lead sponsor | University of Cincinnati |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 52 |
| Start date | 2007-08 |
| Completion | 2009-09 |
Conditions
- Traumatic Brain Injury
- Subarachnoid Hemorrhage
Interventions
- Levetiracetam
- Phenytoin
Primary outcomes
- Seizure Incidence — Duration of study, up to 6 months after the injury
This was the number of patients in each group who demonstrated seizure activity during the course of the study
Countries
United States